Immix Biopharma (IMMX) EPS (Weighted Average and Diluted) (2022 - 2026)
Immix Biopharma's (IMMX) quarterly EPS (Weighted Average and Diluted) came in at -$0.18 in Q1 2026, down 20.0% year-on-year from -$0.22 in Q1 2025, and up 35.71% quarter-over-quarter from -$0.28 in Q4 2025.
Immix Biopharma (IMMX) EPS (Weighted Average and Diluted) (2022 - 2026) Analysis & Trends
Immix Biopharma has disclosed EPS (Weighted Average and Diluted) across 5 years of filings, most recently posting -$0.18 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.18, down 20.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.92 (down 31.43% YoY), and the FY2025 annual result was -$0.89, down 17.11% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.18 for Q1 2026 at Immix Biopharma, up from -$0.28 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.11 in Q2 2022 to a low of -$0.28 in Q4 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.22 (2024), against an average of -$0.2.
- Across the five-year window, EPS (Weighted Average and Diluted) plunged 118.18% in 2023 and jumped 37.5% in 2024, its largest moves.
- Immix Biopharma's EPS (Weighted Average and Diluted) stood at -$0.27 in 2022, then climbed by 11.11% to -$0.24 in 2023, then jumped by 33.33% to -$0.16 in 2024, then sank by 75.0% to -$0.28 in 2025, then soared by 35.71% to -$0.18 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.18 (Q1 2026), -$0.28 (Q4 2025), and -$0.24 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Immix Biopharma | 467.59 Mn | 467.59 Mn | - | -0.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.18 |
| Dec 31, 2025 | -0.28 |
| Sep 30, 2025 | -0.24 |
| Jun 30, 2025 | -0.22 |
| Mar 31, 2025 | -0.15 |
| Dec 31, 2024 | -0.16 |
| Sep 30, 2024 | -0.24 |
| Jun 30, 2024 | -0.15 |
| Mar 31, 2024 | -0.22 |
| Dec 31, 2023 | -0.24 |
| Sep 30, 2023 | -0.23 |
| Jun 30, 2023 | -0.24 |
| Mar 31, 2023 | -0.18 |
| Dec 31, 2022 | -0.27 |
| Sep 30, 2022 | -0.11 |
| Jun 30, 2022 | -0.11 |